2012-05-11 18:00:34 UTC

Comments Needed on Colon Cancer Technical Review

May 17, 2012

The Agency for Healthcare Research and Quality welcomes comments on a draft technical review on gene expression profiling for predicting outcomes in patients with stage II colon cancer.

The Agency for Healthcare Research and Quality Effective Health Care Program posted the following draft technical review on their program website and welcomes comments until June 4, 2012:

  • Gene Expression Profiling for Predicting Outcomes in Patients with Stage II Colon Cancer. View and comment

While adjuvant chemotherapy is recommended in patients with stage III colon cancer, its role in stage II disease is unclear. In treating 100 stage II patients with adjuvant chemotherapy, three or four will benefit, while others will suffer significant adverse effects. Research is underway to improve this decision-making. Gene expression profiling (GEP) is one of the techniques being studied.

The objective of this technical brief is to provide a summary of the state of the science on use of GEP in predicting outcomes, including response to adjuvant chemotherapy, in patients with stage II colon cancer. This brief also summarizes key uncertainties.

View the draft review.

More on Colorectal Cancer

Principles of GI for the NP and PA

Aug. 10, 2018

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

2018 AGA Postgraduate Course

June 2, 2018

Secure your spot for this clinically focused, multi-topic course that offers immediately applicable information. Held in conjunction with DDW®. Save $75 when you register by April 18.

Advocate CMS, close the colonoscopy loophole

March 8, 2018

AGA urges CMS to address the cost sharing problem that arises when screening colonoscopies become diagnostic for Medicare patients.